Ryan Bearer, DO
Interventional Pain Medicine · Winchester, TNNPI 1407050842
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Nevro Corp. accounts for 68.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $15,251 and has fallen 94.1% since, to $903 in 2025. Among interventional pain medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $98.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$24K
- Medtronic$5K
- Vertiflex, Inc.$2K
- Boston Scientific$1K
- Globus Medical$345
- AbbVie$247
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$17,79351%
- Travel & lodging$4,86614%
- Food & beverage$10,81531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 121 | $23,876 |
| Medtronic(2 entities) | 81 | $4,994 |
| Vertiflex, Inc. | 18 | $1,951 |
| Boston Scientific | 53 | $1,267 |
| Globus Medical | 8 | $345 |
| AbbVie | 11 | $247 |
| Painteq LLC | 6 | $234 |
| Vertos Medical, Inc. | 4 | $209 |
| Nalu Medical, Inc. | 5 | $197 |
| Curonix LLC | 2 | $142 |
| Averitas Pharma Inc. | 2 | $133 |
| Stryker | 6 | $130 |
| MML US, Inc. | 1 | $122 |
| Collegium Pharmaceutical, Inc. | 7 | $118 |
| Abbott | 2 | $111 |
| Smoky Mountain Surgical LLC | 1 | $70 |
| Tersera Therapeutics LLC | 3 | $69 |
| Saluda Medical Americas, Inc. | 3 | $62 |
| Biotronik NRO, Inc. | 2 | $61 |
| Spinefrontier, Inc. | 1 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Novartis | 1 | $49 |
| Relievant Medsystems, Inc. | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $16 |
| Amgen | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| SPR Therapeutics, Inc | 1 | $15 |
| Sentynl Therapeutics, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$13,522
- Omnia$4,256
- Senza$3,629
- INTELLIS$2,978
- Superion ISS$1,515
- WaveWriter Alpha Prime 16$144
- ReActiv8$122
- GENERAL PAIN MANAGEMENT$121
- mild Device Kit$118
- PAINTEQ$114
- Qutenza$110
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$110
- Nalu Neurostimulation System$108
- INTELLIS ADAPTIVESTIM$102
How this compares
$34,673 in reported general payments places this provider in the 95th percentile of 41 interventional pain medicine providers in Tennessee.
See all interventional pain medicine providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 20 | $18,496 |
| Buprenorphine | 37 | $8,278 |
| Xtampza ErOxycodone Myristate | 12 | $7,841 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 204 | $6,892 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 206 | $5,555 |
| Gabapentin | 187 | $2,721 |
| Duloxetine Hcl | 193 | $2,305 |
| Tizanidine Hcl | 72 | $2,001 |
| Morphine Sulfate ErMorphine Sulfate | 58 | $1,821 |
| Lidocaine | 13 | $1,694 |
| Naloxone Hcl | 20 | $1,426 |
| Pregabalin | 117 | $1,398 |
| Diclofenac Sodium | 17 | $634 |
| Oxycodone Hcl | 49 | $592 |
| Baclofen | 39 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $118 | $26,33832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 interventional pain medicine providers in Tennessee.
Other interventional pain medicine in Winchester
- William NewtonWinchester$225K
- Michael WilkinsonJohnson City$35K
- Jacob MillsMountain Home$24K
- Matthew KangasMemphis$22K
- Matthew RupertFranklin$17K
- Adolfo CuadraKnoxville$15K
- Cameron ShawverJohnson City$15K
- Christine LeslieMorristown$12K
- Madhu YelameliColumbia$12K
- John WelkerAntioch$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.